首发精神分裂症患者体重偏瘦与认知功能的关系
The Relationship between Underweight and Cognitive Function in First-Episode Schizophrenia
DOI: 10.12677/AP.2022.124153, PDF,    科研立项经费支持
作者: 李 娜, 宇淑涵, 王朝敏, 辛 博, 李 永, 余 明*：河北医科大学精神卫生中心，河北省精神心理健康评估与干预技术创新中心，河北 石家庄；河北省精神心理疾病临床研究中心及河北省精神卫生研究所，河北 石家庄；河北医科大学第一医院精神卫生科，河北 石家庄；河北省脑科学与精神心理疾病重点实验室，河北 石家庄；河北省脑老化与认知神经科学实验室，河北 石家庄
关键词: 首发精神分裂症患者；认知功能；体重指数；First-Episode Schizophrenia Patients； Cognitive Function； Body Mass Index
摘要: 目的：探讨首发精神分裂症患者偏瘦对认知功能的影响。方法：本研究纳入首发精神分裂症患者，按照BMI不同将其分为两组，对每一位患者的身高、体重、认知功能进行测评。结果：BMI与数字符号呈正相关，与连线测验A及连线测验B所用时间呈负相关；体重正常组数字符号、连线测验A及连线测验B的成绩好于体重偏瘦组。结论：BMI能够影响认知，体重偏瘦的首发精神分裂症患者认知功能低于体重正常组的患者，体重越瘦其认知功能越差。
Abstract: Objective: The purpose of our study was to investigate the influence of underweight on cognitive function. Methods: The study recruited patients with first-episode schizophrenia, and they were divided into two groups according to BMI. The data of height, weight, and cognitive functions of the patients were collected. Results: There was a positive correlation between the BMI and Digit Symbol. There was a negative correlation between the BMI and Trail Making Test A and Trail Making Test B. Underweight patients with schizophrenia had significantly lower scores than the patients with normal weight on the Digit Symbol, Trail Making Test A and Trail Making Test B. Conclusion: Our study suggests that BMI can affect cognitive function; the cognitive function of the underweight patients is lower than the patients with normal weight; the lower the weight, the worse the cognitive function.
文章引用：李娜, 宇淑涵, 王朝敏, 辛博, 李永, 余明 (2022). 首发精神分裂症患者体重偏瘦与认知功能的关系. 心理学进展, 12(4), 1291-1296. https://doi.org/10.12677/AP.2022.124153

参考文献

[1] 李娜, 刘善明, 邓伟, 张波, 耿婷, 张树森, 黄明敏, 李涛, 邓红(2012). 首发精神分裂症患者治疗后体质指数与认知功能的关系. 中国预防医学杂志, 13(6), 415-418.
[2] 刘军军, 程敏, 邵阿林, 曹慧, 吴兵, 龚有山, 邹玉青, 张向荣(2018). 社区精神分裂症患者低体重率及相关因素分析. 中国神经精神疾病杂志, 44(5), 277-282.
[3] Basson, B. R., Kinon, B. J., Taylor, C. C., Szymanski, K. A., Gilmore, J. A., & Tollefson, G. D. (2001). Factors Influencing Acute Weight Change in Patients with Schizophrenia Treated with Olanzapine, Haloperidol, or Risperidone. Journal of Clinical Psychiatry, 62, 231-238.[CrossRef] 
[4] Elias, M. F., Elias, P. K., Sullivan, L. M., Wolf, P. A., & D’Agostino, R. B. (2003). Lower Cognitive Function in the Presence of Obesity and Hypertension: The Framingham Heart Study. International Journal of Obesity and Related Metabolic Disorders, 27, 260-268.[CrossRef] [PubMed]
[5] Gunstad, J., Lhotsky, A., Wendell, C. R., Ferrucci, L., & Zonderman, A. B. (2010). Longitudinal Examination of Obesity and Cognitive Function: Results from the Baltimore Longitudinal Study of Aging. Neuroepidemiology, 34, 222-229.[CrossRef] [PubMed]
[6] Gunstad, J., Paul, R. H., Cohen, R. A., Tate, D. F., Spitznagel, M. B., & Gordon, E. (2007). Elevated Body Mass Index Is Associated with Executive Dysfunction in Otherwise Healthy Adults. Comprehensive Psychiatry, 48, 57-61.[CrossRef] [PubMed]
[7] Guo, X., Zhang, Z., Wei, Q., Lv, H., Wu, R., & Zhao, J. (2013). The Relationship between Obesity and Neurocognitive Function in Chinese Patients with Schizophrenia. BMC Psychiatry, 13, Article No. 109.[CrossRef] 
[8] Gustafson, D., Lissner, L., Bengtsson, C., Bjorkelund, C., & Skoog, I. (2004). A 24-Year Follow-Up of Body Mass Index and Cerebral Atrophy. Neurology, 63, 1876-1881. https://pubmed.ncbi.nlm.nih.gov/15557505/[CrossRef] 
[9] Gustafson, D., Rothenberg, E., Blennow, K., Steen, B., & Skoog, I. (2003). An 18-Year Follow-Up of Overweight and Risk of Alzheimer Disease. Archives of Internal Medicine, 163, 1524-1528.[CrossRef] [PubMed]
[10] Hill, S. K., Schuepbach, D., Herbener, E. S., Keshavan, M. S., & Sweeney, J. A. (2004). Pretreatment and Longitudinal Studies of Neuropsychological Deficits in Antipsychotic-Naïve Patients with Schizophrenia. Schizophrenia Research, 68, 49-63.[CrossRef] 
[11] Horrobin, D. F. (1998). The Membrane Phospholipid Hypothesis as a Biochemical Basis for the Neurodevelopmental Concept of Schizophrenia. Schizophrenia Research, 30, 193-208.[CrossRef] 
[12] Kinon, B. J., Basson, B. R., Gilmore, J. A., & Tollefson, G. D. (2001). Long-Term Olanzapine Treatment: Weight Change and Weight-Related Health Factors in Schizophrenia. Journal of Clinical Psychiatry, 62, 92-100.[CrossRef] 
[13] Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kareholt, I., Winblad, B. et al. (2005). Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease. Archives of Neurology, 62, 1556-1560.[CrossRef] [PubMed]
[14] Krug, A., Stein, F., & Kircher, T. (2020). [Cognitive Disorders in Schizophrenia]. Nervenarzt, 91, 2-9.[CrossRef] [PubMed]
[15] Meltzer, H. Y., Perry, E., & Jayathilake, K. (2003). Cloza-pine-Induced Weight Gain Predicts Improvement in Psychopathology. Schizophrenia Research, 59, 19-27.[CrossRef] 
[16] Salokangas, R., Honkonen, T., Stengard, E., & Hietala, J. (2007). Body Mass Index and Functioning in Long-Term Schizophrenia. Results of the DSP Project. European Psychiatry, 22, 313-318.[CrossRef] [PubMed]
[17] Snitz, B. E., Macdonald 3rd, A. W., & Carter, C. S. (2006). Cognitive Deficits in Unaffected First-Degree Relatives of Schizophrenia Patients: A Meta-Analytic Review of Putative Endophenotypes. Schizophrenia Bulletin, 32, 179-194.[CrossRef] [PubMed]